--- title: Institute@Precision | Biopharma Research Insights description: Discover biopharma research insights from Institute@Precision experts across development, commercialization and precision medicine innovation. --- Institute@Precision # Insight for what’s next The Institute@Precision was created to bring together the people driving discovery, development, and delivery, and to turn their collective experience into shared insight. It's a collaborative space for learning, connecting, and accelerating progress across the entire precision development and commercialization pathway.​ [![Explore insights](https://no-cache.hubspot.com/cta/default/5014803/cd92ce0c-92e7-4ce9-9028-44c3c0cdca72.png)](https://cta-redirect.hubspot.com/cta/redirect/5014803/cd92ce0c-92e7-4ce9-9028-44c3c0cdca72) [![Engage experts](https://no-cache.hubspot.com/cta/default/5014803/325e6f55-05b8-4dc0-8e07-101716ed10a9.png)](https://cta-redirect.hubspot.com/cta/redirect/5014803/325e6f55-05b8-4dc0-8e07-101716ed10a9) By the numbers ## Perspectives that span R&D and commercialization​ Access perspectives that are deeply rooted in real world experience, across the entire drug lifecycle, from early research through development, access and commercialization.  25 + years conducting oncology trials 700 + clinical trials supported worldwide 150 + PhDs, MDs and PharmDs 450 + launches and label expansions The Institute@Precision Asia-Pacific Series Commercialization & Access ### China Market Access After NRDL Maturity: What Comes After the Price Reset? [Read More](https://www.instituteatprecision.com/insights/apac-nrdl) Research & Development ### The APAC Imperative for Phase III Trials [Read More](https://www.instituteatprecision.com/insights/phase-iii-apac) Commercialization & Access ### The Role of Societal Value Analyses in Supporting Access to Novel Pharmacotherapies in Asia-Pacific Markets [Read More](https://www.instituteatprecision.com/insights/societal-value-apac) ![China Market Access After NRDL Maturity: What Comes After the Price Reset? Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/China%20Market%20Access%20After%20NRDL%20Maturity-What%20Comes%20After%20the%20Price%20Reset.jpg?length=720&name=China%20Market%20Access%20After%20NRDL%20Maturity-What%20Comes%20After%20the%20Price%20Reset.jpg) Commercialization & Access | White Paper China Market Access After NRDL Maturity: What Comes After the Price Reset? NRDL inclusion is no longer the finish line. See why reimbursement alone doesn’t guarantee real-world utilization. [ Read More ](https://www.instituteatprecision.com/insights/apac-nrdl) ![The APAC Imperative for Phase III Trials Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/The%20APAC%20Imperative%20for%20Phase%20III%20Trials.jpg?length=720&name=The%20APAC%20Imperative%20for%20Phase%20III%20Trials.jpg) Research & Development | White Paper The APAC Imperative for Phase III Trials The benefits of running your Phase III trial in APAC are established.​ Learn why so many organizations struggle to realize them. [ Read More ](https://www.instituteatprecision.com/insights/phase-iii-apac) ![The Role of Societal Value Analyses in Supporting Access to Novel Pharmacotherapies in Asia-Pacific Markets Image](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Asset%20Thumbnails/The%20Role%20of%20Societal%20Value%20Analyses%20in%20Supporting%20Access%20to%20Novel%20Pharmacotherapies%20in%20Asia-Pacific%20Markets.jpg?length=720&name=The%20Role%20of%20Societal%20Value%20Analyses%20in%20Supporting%20Access%20to%20Novel%20Pharmacotherapies%20in%20Asia-Pacific%20Markets.jpg) Commercialization & Access | White Paper The Role of Societal Value Analyses in Supporting Access to Novel Pharmacotherapies in Asia-Pacific Markets See how looking beyond clinical value can strengthen your case with payers and policymakers. [ Read More ](https://www.instituteatprecision.com/insights/societal-value-apac) Institute@Precision Series ## One hot topic every quarter. Multiple expert perspectives. Each Institute@Precision series puts a timely issue under the microscope. Through the eyes of experts from across the healthcare continuum, we explore the challenges and opportunities that determine how innovations reach patients.  ![homepage-APAC-card-1](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Images/homepage-APAC-card-1.webp?length=720&name=homepage-APAC-card-1.webp) Asia-Pacific Opportunity and complexity are growing APAC’s impact is no longer regional. It is redefining how innovative therapies move from development to global markets. What does it take to turn APAC’s emerging opportunities into strategic advantage? [ Explore series ](https://www.instituteatprecision.com/apac) ![radiopharm-topic-card](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Images/radiopharm-topic-card.webp?length=720&name=radiopharm-topic-card.webp) Radiopharmaceuticals Tuning out the noise Radiopharmaceuticals are attracting unprecedented attention, investment and optimism. Our quarterly series cuts through the complexities, bringing together expert points of view on the research, regulatory, operational and commercial realities driving the narrative.   [ Explore series ](https://www.instituteatprecision.com/radiopharmaceuticals) ![adcs-topic-card](https://www.instituteatprecision.com/hs-fs/hubfs/Institute%20at%20Precision%20Website/Images/adcs-topic-card.webp?length=720&name=adcs-topic-card.webp) Antibody-Drug Conjugates Promises, pressure and progress. ADCs have transformed oncology, but the road ahead is far from straightforward. Explore the perspectives, lessons and strategic considerations influencing the next era of ADC development.  [ Explore series ](https://www.instituteatprecision.com/antibody-drug-conjugates) Subscribe today ## Insights in your inbox Institute@Precision works as an ever-evolving dialogue. Go deep into emerging topics, surface your own perspectives and help influence the crucial conversations happening across biopharma.  Join the conversation   Inside the institute ## See what the experts see. ### **Moving from molecule to market with Precision** Institute@Precision draws on expertise from across Precision Medicine Group. Together our organizations span the spectrum from molecule to market, providing actionable answers to the most pressing questions in healthcare innovation, from multiple angles.   [ Meet experts ](https://www.instituteatprecision.com/experts) ![precision-medicine-group](https://www.instituteatprecision.com/hs-fs/hubfs/institute-at-precision-u5/branding/precision-medicine-group.png?length=720&name=precision-medicine-group.png) Precision Solutions Precision in every stage Precision Medicine Group is a global team of 3,500 experts operating across two groups: Precision for Medicine and Precision AQ, supporting life science organizations from the lab to trials to launch and through product maturity.​ [ Learn more ](https://www.precisionmedicinegrp.com/) ![precision-for-medicine](https://www.instituteatprecision.com/hs-fs/hubfs/institute-at-precision-u5/branding/precision-for-medicine.png?length=720&name=precision-for-medicine.png) Research & Development Next-gen clinical development​​​ Precision for Medicine helps sponsors navigate the complex development pathway through scientific expertise, clinical excellence and data-driven insights.   [ Learn more ](https://www.precisionformedicine.com/) ![precision_aq-logo-horizontal-2_color-RGB_reverse_R](https://www.instituteatprecision.com/hs-fs/hubfs/precision_aq-logo-horizontal-2_color-RGB_reverse_R.png?length=720&name=precision_aq-logo-horizontal-2_color-RGB_reverse_R.png) Commercialization Opening up access Precision AQ helps innovators translate evidence into action, combining strategy, insight and communications expertise to enable broader access to life-changing medicines.   [ Learn more ](https://www.precisionaq.com/en-gb/) The experts’ view ## Meet the people behind the progress Continue the conversation alongside the experts. From development to commercialization, their perspectives are helping to shape the future for precision medicines.  [![Contact Us](https://no-cache.hubspot.com/cta/default/5014803/d1ca9cb8-7593-4a82-ae08-f0fcca9c76f3.png)](https://cta-redirect.hubspot.com/cta/redirect/5014803/d1ca9cb8-7593-4a82-ae08-f0fcca9c76f3)